We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

75 hedge funds and large institutions have $233M invested in Kindred Biosciences, Inc. in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

4% more funds holding

Funds holding: 7275 (+3)

4% less capital invested

Capital invested by funds: $242M → $233M (-$8.65M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
75
Holders Change
+3
Holders Change %
+4.17%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
33
Reduced
16
Closed
10
Calls
$437K
Puts
Net Calls
+$437K
Net Calls Change
+$478K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
51
Bank of America
North Carolina
$128K -$320K -31,553 -69%
MIM
52
MetLife Investment Management
New Jersey
$126K
Prudential Financial
53
Prudential Financial
New Jersey
$123K +$136K +13,394 New
VOYA Investment Management
54
VOYA Investment Management
Georgia
$117K
Barclays
55
Barclays
United Kingdom
$114K +$122K +12,057 +3,029%
Goldman Sachs
56
Goldman Sachs
New York
$113K -$208K -20,508 -62%
MAM
57
Meeder Asset Management
Ohio
$109K +$17.3K +1,706 +17%
CSS
58
Cubist Systematic Strategies
Connecticut
$107K +$118K +11,659 New
OAM
59
Oxford Asset Management
United Kingdom
$99K +$109K +10,767 New
FC
60
Fairpointe Capital
Illinois
$92K
Citigroup
61
Citigroup
New York
$90K +$22.1K +2,181 +29%
MLICM
62
Metropolitan Life Insurance Company (MetLife)
New York
$88.5K
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$68.9K +$76.3K +7,509 +83,433%
Legal & General Group
64
Legal & General Group
United Kingdom
$55K +$13.9K +1,371 +29%
Marshall Wace
65
Marshall Wace
United Kingdom
$53K +$58.5K +5,760 New
AIP
66
Ameritas Investment Partners
Nebraska
$24K
CFG
67
Citizens Financial Group
Rhode Island
$17K +$19.3K +1,900 New
FCMT
68
Founders Capital Management (Texas)
Texas
$14K
LTFS
69
Ladenburg Thalmann Financial Services
Florida
$9K +$10.2K +1,000 New
Federated Hermes
70
Federated Hermes
Pennsylvania
$7K -$16.1K -1,584 -70%
TRCT
71
Tower Research Capital (TRC)
New York
$6K +$3.95K +389 +165%
Carson Wealth (CWM LLC)
72
Carson Wealth (CWM LLC)
Nebraska
$6K +$6.87K +676 New
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$2K +$386 +38 +19%
PHK
74
Point72 Hong Kong
Hong Kong
$2K +$2.29K +226 New
Bank of Montreal
75
Bank of Montreal
Ontario, Canada
$1K -$3.42K -337 -70%

KIN Hedge Fund Activity: Q1 2019 in Review

75 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q1 2019, worth a combined $233M — down 3.6% from $242M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new KIN positions and 10 closed out — a net gain of 3 holders — while 33 added to existing stakes and 16 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $8.05M. The largest seller was Morgan Stanley, cutting an estimated $6.98M.

  • 75 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q1 2019, up from 72 in Q4 2018.
  • Funds reported $233M of Kindred Biosciences, Inc. stock for Q1 2019, down 3.6% quarter-over-quarter.
  • 13 funds opened new Kindred Biosciences, Inc. positions in Q1 2019 and 10 closed out, a net change of +3 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q1 2019 was Deutsche Bank, an estimated $8.05M added.
  • The largest Kindred Biosciences, Inc. seller in Q1 2019 was Morgan Stanley, an estimated $6.98M sold.

Based on aggregated 13F filings for Q1 2019.